Please assess the completion status of the following clinical trial:

Trial Title: Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Programmed abdominal or thoracic surgery~* Patients \> 18 yrs~* Patients are aware of German language~* Participation is voluntary~* ASA-risk class 1-2 (American Society of Anesthesiologists guidelines)~Exclusion Criteria:~* Severe cardiac, pulmonary, renal or neurologic disease~* ASA risk III and IV~* Insulin dependent Diabetes mellitus~* Polyneuropathy~* Chronic pain~* Use of analgesic drugs~* Ulcus duodeni~* Ulcus ventriculi~* Time after intestinal bleeding~* Allergy reactions towards coxibes or coxibe-like drugs~* Pregnancy and lactation~* Severe hepatic disease (Albumin \< 25 g/l or Child-Pugh-Score ≥ 10)~* Children and Teenager \< 16 years~* Chronic intestinal inflammation~* Heart failure (NYHA II - IV)~* Inbalancend arterial hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preemptive (Type: ACTIVE_COMPARATOR): Preemptive group patients get Etoricoxibe twice (before and after surgery) or just a single preoperative dose
- Postoperative (Type: PLACEBO_COMPARATOR): Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).